正在加载公司
Just reported
From Pulmonx's results release of 2026年10月27日; its quarterly report has since been filed.
Actual
US$22.8M
+6.2% y/y
+0.3% q/q
Guided
—
No guide given
Actual
-US$0.19
Guided
—
No guide given
Actual
-US$7.5M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Pulmonx is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plcUS$131.6BA+
SYKStryker Corp.US$117.9BA+
EWEdwards Lifesciences CorporationUS$61.6BA+
GEHCGE Healthcare Technologies Inc.US$37.5BA
GKOSGlaukos CorpUS$14.5BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now AEWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now AGEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now A基于 Pulmonx Corporation 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。
公司指引：2026 财年营收 US$90M 至 US$92M — 同比增长 0.6%，低于刚公布的 6.2%
Grade D-
价格下方的色带显示每个日期的评级，仅依据当时已公开的文件计算。
显示 Pulmonx Corporation 评级历史 24 个季度中的 2 个。 其余 22 个可回溯到 2021年3月。
